MSLN/MSLN蛋白Recombinant Human M

纯度：

Greater than 85% as determined by SDS-PAGE.

基因名：

MSLN

Uniprot No.：

Q13421

别名：

CAK 1; CAK1; CAK1 antigen; cleaved form; Megakaryocyte potentiating factor ; Mesothelin; Mesothelin isoform 1 precursor ; MPF; Msln; MSLN_HUMAN; Pre pro megakaryocyte potentiating factor; Pre-pro-megakaryocyte-potentiating factor; SMR; SMRP; Soluble MPF mesothelin related protein

种属：

Homo sapiens (Human)

蛋白长度：

Partial of Isoform 3

来源：

Mammalian cell

分子量：

61.2 kDa

表达区域：

296-580aa

氨基酸序列：

EVEKTACPSGKKAREIDESLIFYKKWELEACVDAALLATQMDRVNAIPFTYEQLDVLKHKLDELYPQGYPESVIQHLGYLFLKMSPEDIRKWNVTSLETLKALLEVNKGHEMSPQVATLIDRFVKGRGQLDKDTLDTLTAFYPGYLCSLSPEELSSVPPSSIWAVRPQDLDTCDPRQLDVLYPKARLAFQNMNGSEYFVKIQSFLGGAPTEDLKALSQQNVSMDLATFMKLRTDAVLPLTVAEVQKLLGPHVEGLKAEERHRPVRDWILRQRQDDLDTLGLGLQG

蛋白标签：

C-terminal hFc-tagged

产品提供形式：

Liquid or Lyophilized powder

缓冲液：

If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.

货期：

3-7 business days

注意事项：

Repeated freezing and thawing is not recommended. Store working aliquots at 4℃ for up to one week.

功能：

Antibodies against MSLN are detected in patients with mesothelioma and ovarian cancer.

内毒素：

Not test.

SDS-PAGE:

(Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

LC-MS Image Description/Western Blot:

/

Product types:

In Stock Protein

Biological_Activity:

/

Research Areas:

Cancer

Reconstitution:

We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.

Reference:

"Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients." Ho M., Hassan R., Zhang J., Wang Q.-C., Onda M., Bera T., Pastan I. Clin. Cancer Res. 11:3814-3820(2005)

Function:

/